Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
First KRAS targeted therapy shows promise for lung and colon cancer
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
FDA says studies of new breast cancer treatments should allow enrollment of men as well as women.
Treatment involves selecting, multiplying and reinfusing cancer-fighting immune cells.
A three-pronged approach could offer hope for people with hard-to-treat advanced pancreatic cancer.
AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”
New initiative will help health care providers navigate the process of submitting expanded access requests.
Nine organizations join forces to make clinical trial information available, paving the way for improved patient matching.
Eighty percent of medications that receive accelerated approval don’t extend overall survival.
All 12 treated children with NTKR, ROS1 or ALK gene abnormalities showed partial or compete tumor shrinkage.
Clinical trials often exclude key patient populations, including children and people living with HIV or hepatitis B or C.
NKTR-214 plus Opdivo as first-line therapy had an overall response rate of 48 percent.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.